Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer
Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer
复制标题
DOI：
10.1007/s12032-019-1314-9
复制
发表时间：
2019-10-01
期刊：
影响因子：
3.4
通讯作者：
Saito, Mitsue
中科院分区：
文献类型：
--
作者：
Ito, Mayuko;Horimoto, Yoshiya;Saito, Mitsue
几项临床研究检测了循环肿瘤细胞(CTCs)。然而，CTCs作为乳腺癌患者预测/预后标志物的应用尚未建立，尤其是选择合适的标志物来检测CTCs。最近，我们研究了接受了灯盏花素治疗的转移性乳腺癌患者的CTC，包括间质状态。我们发现，对间质和上皮性CTC的评估对于预测eriBulin的反应性可能很重要。在目前的研究中，我们跟踪观察了这些患者在接受eribuin治疗后的结果，并调查了CTC分析结果作为该患者群体预后标志物的可能性。21名患者入选，并在使用淫羊藿素治疗前采集外周血样本。然后使用微流控芯片设备对CTCs进行检测。波形蛋白和泛细胞角蛋白阳性的CTCs分别定义为间叶性CTCs和上皮性CTCs。根据CTC数量和临床病理因素评估总存活率(OS)。在观察期间，13例患者(62%)死于乳腺癌，中位OS为18个月。高级别肿瘤和高CTC总数的患者的OS明显短于那些低级别肿瘤和较小的CTC负担的患者(p分别为0.026和0.037)。接受灯盏花素作为转移性疾病的第一化疗方案的患者有较长的OS(p=0.006)。我们的数据表明，测定间充质和上皮性CTC的数量可能预测接受灯盏花素治疗的患者的存活率。
Several clinical studies have examined circulating tumour cells (CTCs). However, the application of CTCs as a predictive/prognostic marker for breast cancer patients has yet to be established, particularly the selection of suitable markers for detecting CTCs. We recently investigated CTCs, including mesenchymal status, from metastatic breast cancer patients who had received eribulin-based treatment. We found that assessment of both mesenchymal and epithelial CTCs might be important for predicting eribulin responsiveness. In the current study, we followed up the outcomes of these patients after eribulin treatment and investigated the possibility of CTC analysis results serving as prognostic markers for this patient population. Twenty-one patients were enrolled and peripheral blood samples were collected before eribulin-based treatments. CTCs were then examined using a Microfluidic Chip device. CTCs positive for vimentin and pan-cytokeratin were defined as mesenchymal and epithelial CTCs, respectively. Overall survival (OS) was assessed in relation to the number of CTCs and clinicopathological factors. During the observation period, 13 patients (62%) died due to breast cancer and the median OS was 18 months. Patients with high-grade tumours and a high total number of CTCs showed significantly shorter OS than those with low-grade tumours and smaller CTC burdens (p = 0.026 and 0.037, respectively). Patients who received eribulin as the first chemotherapy for metastatic disease showed longer OS (p = 0.006). Our data suggest that determining numbers of both mesenchymal and epithelial CTCs might predict survival for patients receiving eribulin.